GB202014851D0 - SARS-COV-2 antibodies - Google Patents

SARS-COV-2 antibodies

Info

Publication number
GB202014851D0
GB202014851D0 GBGB2014851.6A GB202014851A GB202014851D0 GB 202014851 D0 GB202014851 D0 GB 202014851D0 GB 202014851 A GB202014851 A GB 202014851A GB 202014851 D0 GB202014851 D0 GB 202014851D0
Authority
GB
United Kingdom
Prior art keywords
cov
sars
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2014851.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iontas Ltd
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontas Ltd filed Critical Iontas Ltd
Priority to GBGB2014851.6A priority Critical patent/GB202014851D0/en
Publication of GB202014851D0 publication Critical patent/GB202014851D0/en
Priority to GBGB2020310.5A priority patent/GB202020310D0/en
Priority to PCT/EP2021/075955 priority patent/WO2022058618A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
GBGB2014851.6A 2020-09-21 2020-09-21 SARS-COV-2 antibodies Ceased GB202014851D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2014851.6A GB202014851D0 (en) 2020-09-21 2020-09-21 SARS-COV-2 antibodies
GBGB2020310.5A GB202020310D0 (en) 2020-09-21 2020-12-21 Sars-cov-2 antobodies
PCT/EP2021/075955 WO2022058618A2 (en) 2020-09-21 2021-09-21 Sars-cov2 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2014851.6A GB202014851D0 (en) 2020-09-21 2020-09-21 SARS-COV-2 antibodies

Publications (1)

Publication Number Publication Date
GB202014851D0 true GB202014851D0 (en) 2020-11-04

Family

ID=73196763

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2014851.6A Ceased GB202014851D0 (en) 2020-09-21 2020-09-21 SARS-COV-2 antibodies
GBGB2020310.5A Ceased GB202020310D0 (en) 2020-09-21 2020-12-21 Sars-cov-2 antobodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2020310.5A Ceased GB202020310D0 (en) 2020-09-21 2020-12-21 Sars-cov-2 antobodies

Country Status (2)

Country Link
GB (2) GB202014851D0 (en)
WO (1) WO2022058618A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929786A (en) * 2021-04-13 2022-01-14 武汉大学 Novel coronavirus mutant strain S protein and subunit vaccine thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
GB201720351D0 (en) 2017-12-06 2018-01-17 Iontas Ltd Selecting for developability in drug discovery
CN114163523B (en) * 2020-03-17 2023-07-18 北京凯因科技股份有限公司 Single-domain antibody for novel coronavirus and application thereof
CN111592595B (en) * 2020-04-27 2021-02-19 南京医科大学 Neutralizing antibody against novel coronavirus SARS-Cov-2 and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929786A (en) * 2021-04-13 2022-01-14 武汉大学 Novel coronavirus mutant strain S protein and subunit vaccine thereof
CN113929786B (en) * 2021-04-13 2022-08-05 武汉大学 Novel coronavirus mutant strain S protein and subunit vaccine thereof

Also Published As

Publication number Publication date
WO2022058618A3 (en) 2022-04-28
WO2022058618A2 (en) 2022-03-24
GB202020310D0 (en) 2021-02-03

Similar Documents

Publication Publication Date Title
HUE062777T2 (en) Antibodies against sars-cov-2
IL289112A (en) Anti-tigit antibodies
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
GB201905150D0 (en) Ant-ige antibodies
GB201917480D0 (en) Antibodies
IL308741A (en) Anti-sirp-alpha antibodies
GB201900732D0 (en) Antibodies
IL300142A (en) ANTI-IL13Ralpha2 ANTIBODIES
GB202105110D0 (en) Anti-CD73 antibodies
IL289160A (en) Anti-angpt2 antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
GB202015115D0 (en) ZIP12 Antibody
IL311043A (en) Anti-il-11rα antibodies
IL310245A (en) Anti-hla-g antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
IL307175A (en) Il-38-specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
GB202107517D0 (en) Antibodies
GB202104128D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)